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ABSTRACT
Background The standard treatment for resectable 
advanced esophageal squamous cell carcinoma in Japan 
is surgery followed by neoadjuvant chemotherapy, 
and it is important to predict the effect of neoadjuvant 
chemotherapy before treatment. Therefore, this study 
aims to extract conventional blood examination data, 
such as tumor markers and/or inflammatory/nutritional 
index levels, that can predict the pathological response 
of patients with esophageal squamous cell carcinoma to 
neoadjuvant chemotherapy.
Methods We retrospectively analyzed the medical 
records of 66 patients with thoracic esophageal squa-
mous cell carcinoma who received neoadjuvant chemo-
therapy, followed by curative esophagectomy at Tottori 
University Hospital between June 2009 and December 
2019.
Results We demonstrated that the product of the 
platelet-to-lymphocyte ratio (PLR) multiplied by the 
cytokeratin-19 fragment (CYFRA) level, which was 
termed “PLR-CYFRA,” is the most accurate indicator 
that predicts the pathological response to neoadjuvant 
chemotherapy, with the highest area under the curve 
[0.795 (95% confidence interval: 0.665–0.925), P < 0.001] 
in receiver operating characteristic analyses. Therefore, 
we divided patients into the PLR-CYFRALow (< 237.6, 
n = 21) and PLR-CYFRAHigh (≥ 237.6, n = 45) groups 
and found that the percentage of PLR-CYFRALow was 
significantly higher in patients with a better pathological 
response (P < 0.001). Furthermore, patients with good 
pathological response had significantly better prognoses 
in terms of disease-specific survival (P = 0.014), recur-
rence-free survival (P = 0.014), and overall survival (P 
= 0.032). In the multivariate analysis, PLR-CYFRA was 
an independent predictor of the pathological response 
of patients with esophageal squamous cell carcinoma to 
neoadjuvant chemotherapy (P = 0.002).
Conclusion Pretreatment PLR-CYFRA might be a 
useful and simple tool that predicts the pathological 
effect of neoadjuvant chemotherapy in esophageal 
squamous cell carcinoma.
Key words cytokeratin; esophageal cancer; lympho-
cyte; neoadjuvant chemotherapy; platelet
Esophageal cancer is the sixth leading cause of cancer-
related deaths worldwide,1 and in Japan, the most com-
mon histological type of esophageal cancer is squamous 
cell carcinoma (more than 90%).2 According to the 
results of the JCOG9907 trial, the standard treatment 
for locally advanced and resectable esophageal squa-
mous cell carcinoma (ESCC) is esophagectomy with 
two- or three-field lymphadenectomy after neoadjuvant 
chemotherapy (NAC).3 Despite this intensive combina-
tion therapy, we often find cases with a poor prognosis 
because of postoperative recurrence, and the 5-year 
survival rate after esophagectomy is only 59.3%.2 One 
reason for this poor prognosis is the inadequate effect of 
NAC, as it has been reported that pathological respond-
ers to NAC exhibited better prognosis and that the 
postoperative recurrence pattern often confined to the 
regional field is predominantly a solitary lesion without 
distant recurrence.4 Therefore, although the prediction 
of the NAC effect before treatment is important as it 
determines the treatment strategy, no predictive method 
has been established.
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In recent years, several studies have reported 
that pretherapeutic values of tumor markers might be 
useful in predicting prognosis and NAC efficacy in 
ESCC.5 Furthermore, various inflammatory/nutritional 
biomarkers, such as the neutrophil-to-lymphocyte ratio 
(NLR), platelet-to-lymphocyte ratio (PLR), and prog-
nostic nutritional index (PNI), have been reported to be 
associated significantly with prognosis and to be useful 
in predicting the chemotherapeutic effects in ESCC.6–10 
However, it is unknown whether each indicator alone or 
in combination can predict the effects of NAC in ESCC 
with the highest accuracy.
Therefore, this study aims to evaluate the predic-
tive value of a single indicator or a combination of 
indicators, including tumor markers and inflammatory/
nutritional biomarkers, in predicting NAC efficacy. This 
study also aims to establish the best predictor of NAC 
efficacy in ESCC.
MATERIALS AND METHODS
Patients and NAC regimens
This study was based on a retrospective analysis of 
66 patients with locally advanced thoracic ESCC who 
received NAC, followed by curative esophagectomy 
at Tottori University Hospital between June 2009 and 
December 2019. The clinicopathological findings were 
determined according to the Japanese Classification of 
Esophageal Cancer (11th edition).11, 12 The criteria for 
NAC administration were clinical stage II, III, or IVa 
disease. As standard chemotherapeutic drugs, 5-fluoro-
uracil (5-FU) and cisplatin (FP regimen) were used for 
all eligible patients, except those with impaired renal 
function and those treated with 5-FU and nedaplatin 
(FN regimen). The FP regimen consisted of 80 mg/m2 
cisplatin on day 1 and 800 mg/m2 5-FU infusions on 
days 1–5, whereas the FN regimen consisted of 90 mg/
m2 nedaplatin on day 1 and 800 mg/m2 5-FU infusions 
on days 1–5. The length of one chemotherapy cycle of 
each regimen ranged from 21 to 28 days. Surgery was 
performed 6–8 weeks after the last NAC cycle. The 
standard surgical approach was thoracoscopic subtotal 
esophagectomy and reconstruction with a gastric tube, 
and lymphadenectomies, including two- or three-field 
procedures, were performed.
Criteria of pathological response to NAC
The pathological response was evaluated by patholo-
gists using the primary tumor of the surgical specimens 
according to the Japanese Classification of Esophageal 
Cancer (11th edition),11, 12 as follows: grade 0, no rec-
ognizable cytological or histological therapeutic effect 
is observed; grade 1a, viable cancer cells account for 
two-thirds or more of the tumor tissue; grade 1b, viable 
cancer cells account for between one-third and two-
thirds of the tumor tissue; grade 2, viable cancer cells 
account for less than one-third of the tumor tissue; and 
grade 3, no viable cancer cells are apparent (pathological 
complete response; pCR).
Serum biomarkers
The results of peripheral blood tests, including the detec-
tion of serum albumin (g/dL), C-reactive protein (CRP) 
(mg/dL), squamous cell carcinoma antigen (SCC Ag) 
(ng/mL) and cytokeratin-19 fragment (CYFRA) (ng/
mL) levels, and total platelet, lymphocyte, and neu-
trophil counts (/μL), were obtained from the patients’ 
medical records. Blood test data were obtained within 
1 month of NAC. The NLR and PLR were obtained by 
dividing the peripheral neutrophil count and platelet 
count, respectively, by the peripheral lymphocyte count. 
The PNI was calculated as follows: 10 × peripheral 
serum albumin + 0.005 × peripheral lymphocyte count, 
as reported by Onodera et al.13 The modified Glasgow 
prognostic score (mGPS) was scored as 0, 1, or 2 based 
on CRP (> 1.0 mg/dL) and hypoalbuminemia (<3.5 g/
dL), as described previously.14 The PLR-CYFRA was 
first defined as the PLR value × the serum CYFRA 
level. Our institutional review board approved this study 
(20A234). The need for informed consent was waived.
Statistical analyses
The Youden index was calculated using receiver 
operating characteristic (ROC) curve analysis and 
was defined as the maximum value of “sensitivity 
+ specificity –1”.15, 16 The Youden index value was 
used as an optimal cut-off for the PLR-CYRFA in 
the pathological response, which was used to divide 
patients into the PLR-CYFRAHigh and PLR-CYFRALow 
groups. Survival curves were calculated according to 
the Kaplan–Meier method, and differences between 
the curves were identified using the log-rank test. 
Univariate and multivariate analyses using Cox pro-
portional hazards models were performed to evaluate 
prognostic factors for disease-specific survival (DSS). 
Moreover, to evaluate the effects of clinical variables on 
the pathological response, a univariate analysis was per-
formed using χ2 tests, followed by a multivariate logistic 
analysis. P values < 0.05 were considered significant. 
GraphPad Prism (GraphPad Software, Inc., La Jolla, 
CA) and IBM SPSS Statistics 25 (IBM SPSS, Chicago, 
IL) software were used for the statistical analyses.
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RESULTS
Clinicopathological characteristics
The clinicopathological characteristics of the 66 patients 
with ESCC in this study are shown in Table 1. Of these, 
8 (12.1%) patients were female and 58 (87.9%) were 
male, with a median age of 65 years. The clinical stage 
of ESCC before NAC was II in 29 patients (43.9%), III 
in 36 patients (54.5%), and IVa in 1 patient (1.5%). Fifty-
three patients (80.3%) received the FP regimen and 13 
patients (19.7%) received the FN regimen as NAC. The 
pathological response of the resected tumors after NAC 
was grade 0 in 3 patients (4.5%), grade 1a in 38 patients 
(57.6%), grade 1b in 9 patients (13.6%), grade 2 in 13 
patients (19.7%), and grade 3 (pCR) in 3 patients (4.5%). 
We then divided the 66 patients into the responder (16 
patients with grades 2 or 3) and nonresponder groups (50 
patients with grades 0 or 1).
PLR-CYFRA was valuable in predicting the patho-
logical response to NAC
ROC curves were constructed to evaluate the patho-
logical response, and the area under the curve (AUC) 
values were compared to assess the discriminatory 
ability of SCC Ag, CYFRA, PNI, mGPS, NLR, and 
PLR (Table 2). In this analysis, the AUC values of 
CYFRA, NLR and PLR were particularly higher than 
those of the other indicators. Therefore, we defined 
NLR-CYFRA and PLR-CYFRA as the product of NLR 
and PLR multiplied by CYFRA, respectively. ROC 
analysis showed that PLR-CYFRA was most accurate 
in predicting the pathological response with an AUC 
= 0.795 [95% confidence interval (CI): 0.665–0.925, P 
< 0.001] (Table 2); the optimal cut-off PLR-CYFRA 
value was 237.6. Based on this cut-off, the sensitivity, 
specificity, positive predictive value, and negative pre-
dictive value of PLR-CYFRA for pathological response 
grade ≥ 2 were 0.81, 0.84, 0.62, and 0.93, respectively. 
Then, we divided the patients into the PLR-CYFRALow 
(PLR-CYFRA < 237.6, n = 21) and PLR-CYFRAHigh 
groups (PLR-CYFRA ≥ 237.6, n = 45). Figure 1 shows 
the percentage of PLR-CYFRALow or PLR-CYFRAHigh 
according to the pathological response grade, and the 
percentage of PLR-CYFRALow was found to be signifi-
cantly higher when the pathological response grade was 
higher (P < 0.001). Then, Table 3 shows the correlations 
between the PLR-CYFRA and the clinicopathological 
variables in all patients included in this study. The value 
of PLR-CYFRA was significantly higher in younger 
patients (< 70 years) than in older patients (≥ 70 years: 
P < 0.001), in those with low body mass index (< 18.5) 
than those with high body mass index (≥ 18.5: P = 0.014), 
and in those treated with FN regimen than in those 
treated with FP regimen (P = 0.028).
Pathological response to NAC and pretreatment 
factors had a prognostic impact
We next examined the prognostic impact of the patho-
logical response to NAC and pretreatment factors, in-
cluding PLR-CYFRA. When the pathological response 
was compared between the 2 groups [grade ≥ 2 (n = 16) 
or grade < 2 (n = 50)] using Kaplan–Meier analyses, 
the grade ≥ 2 group had a significantly better prognosis 
in terms of DSS (P = 0.014) (Fig. 2a), recurrence-free 
survival (RFS) (P = 0.014) (Fig. 2b), and overall survival 
(OS) (P = 0.032) (Fig. 2c). Similarly, the prognostic 
comparison between the 2 groups of PLR-CYFRAHigh 
(n = 45) and PLR-CYFRALow (n = 21) showed a signifi-
cantly better prognosis for PLR-CYFRALow in terms 
of DSS (P = 0.014) (Fig. 2d) and RFS (P = 0.001) (Fig. 
2e). However, no significant difference was observed 
in OS (P = 0.111) (Fig. 2f), although there was a trend 
toward a better prognosis. Then, prognostic factor 
analyses of pretreatment factors for DSS showed that 
clinical stage III/IVa (P = 0.016), PNI < 50 (P = 0.024), 
and PLR-CYFRA ≥ 237.6 (P = 0.023) were significant 
factors for a poor prognosis according to a univariate 
analysis (Table 4). In the multivariate analysis, clinical 
stage III/IVa (P = 0.032) and PLR-CYFRA ≥ 237.6 (P 
= 0.030) were extracted as independent poor prognostic 
factors (Table 4).
PLR-CYFRA was an independent predictor of path-
ological response to NAC
Finally, we evaluated the effects of clinical variables on 
the pathological response to NAC. The univariate analy-
sis indicated that NLR (P = 0.009) and PLR-CYFRA (P 
< 0.001) were associated significantly with the patho-
logical response (Table 5). In the multivariate analysis, 
PLR-CYFRA (P = 0.002) was an independent predictor 
of pathological response in patients with ESCC who 
received NAC (Table 5).
DISCUSSION
The purpose of the present study was to extract 
valuable predictors of NAC efficacy in ESCC using 
various factors, including inflammatory/nutritional 
biomarkers and tumor markers. We then demonstrated 
that pretreatment PLR-CYFRA was an independent 
predictor of pathological response and an independent 
prognostic factor for patients with ESCC treated with 
NAC. Furthermore, the pathological response to NAC 
was also correlated with patient prognosis. In this study, 
we demonstrated that the inflammatory biomarker PLR 
and the tumor marker CYFRA were useful predictors 
of NAC effects in ESCC. It is well known that the 
systemic inflammatory response plays an important role 
in tumorigenesis and predicts the survival of patients 
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Table 1. Clinicophathological characteristics
No. of patients = 66
Age (years), median (range) 65 (51–79)
Sex, n (%)
 Female 8 (12.1%)
 Male 58 (87.9%)
Body mass index (kg/m2), median (range) 20.2 (14.6–26.9)
Tumor location, n (%)
 Upper 11 (16.7%)
 Middle 29 (43.9%)
 Lower 26 (39.3%)
Clinical invasion depth, n (%)
 cT1 6 (9.1%)
 cT2 22 (33.3%)
 cT3 38 (57.6%)
Clinical lymph node metastasis, n (%)
 cN0 15 (22.7%)
 cN1 25 (37.9%)
 cN2 23 (34.8%)
 cN3 2 (3.0%)
 cN4 1 (1.5%)
Clinical stage, n (%)
 cStage II 29 (43.9%)
 cStage III 36 (54.5%)
 cStage IVa 1 (1.5%)
Chemotherapy, n (%)
 5-FU + cisplatin 53 (80.3%)
 5-FU + nedaplatin 13 (19.7%)
Differentiation, n (%)
 Moderately differntiated 55 (83.3%)
 Poorly differntiated 9 (13.6%)
 No tumor (pCR) 2 (3.0%)
Lymphatic involvement, n (%)
 ly0 11 (16.7%)
 ly1 32 (48.5%9
 ly2 18 (27.3%)
 ly3 5 (7.6%)
Venous involvement, n (%)
 v0 16 (24.2%)
 v1 30 (45.5%)
 v2 18 (27.3%)
 v3 2 (3.0%)
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with cancer, and inflammation can be assessed easily 
by counting neutrophils, lymphocytes, monocytes, 
and platelets in peripheral blood.17 Specifically, it has 
been reported that PLR can predict the efficacy of 
chemotherapy in non-small cell lung cancer, colorectal 
cancer, and breast cancer.18–20 The mechanism of PLR 
in tumorigenesis may stem from the role of platelets 
in promoting angiogenesis, adhesion, and invasion by 
increasing the production of vascular epidermal growth 
factor and transforming growth factor-β in the tumor 
Table 2. Receiver operating characteristic curve analysis for the predictive value of tumor markers and serum-
based inflammatory indicators of pathological response
AUC 95% CI P
SCC Ag 0.542 0.395–0.689 0.616
CYFRA 0.723 0.577–0.869 0.008
PNI 0.641 0.484–0.798 0.091
mGPS 0.528 0.364–0.691 0.742
NLR 0.683 0.554–0.812 0.028
PLR 0.701 0.553–0.849 0.016
NLR-CYFRA 0.763 0.633–0.893 0.002
PLR-CYFRA 0.795 0.665–0.925 < 0.001
CI, confidence interval.
Table 1. (continued)
No. of patients = 66
Pathological invasion depth, n (%)
 pT0 2 (3.0%)
 pT1 13 (19.7%)
 pT2 17 (25.8%)
 pT3 33 (50.0%)
 pT4a 1 (1.5%)
Pathological lymph node metastasis, n (%)
 pN0 20 (30.3%)
 pN1 17 (25.8%)
 pN2 24 (36.4%)
 pN3 4 (6.1%)
 pN4 1 (1.5%)
Pathological stage, n (%)
 pStage 0 3 (4.5%)
 pStage I 4 (6.1%)
 pStage II 26 (39.4%)
 pStage III 31 (47.0%)
 pStage IVa 2 (3.0%)
Pathological response, n (%)
 Grade 0 3 (4.5%)
 Grade 1a 38 (57.6%)
 Grade 1b 9 (13.6%)
 Grade 2 13 (19.7%)
 Grade 3 3 (4.5%)
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Fig. 1. The percentage of PLR-CYFRA high and low cases according to the pathological response grade. CYFRA, cytokeratin-19 frag-
ment; PLR, platelet-to-lymphocyte ratio.
Table 3. Relationships between PLR-CYFRA and clinicopathological variables in patients with ESCC treated with 
NAC
PLR-CYFRA P
(mean ± standard deviation)
Age (years) < 0.001
 < 70 (n = 46) 525.0 ± 519.4
 ≥ 70 (n = 20) 233.9 ± 144.3
Sex 0.409
 Female (n = 8) 746.1 ± 1079.0
 Male (n = 58) 394.1 ± 287.1
Body mass index (kg/m2) 0.014
 < 18.5 (n = 18) 656.6 ± 734.7
 ≥ 18.5 (n = 48) 354.3 ± 266.8
Tumor location 0.753
 Upper, middle (n = 40) 393.8 ± 293.8
 Lower (n = 26) 502.8 ± 637.7
Invasion depth 0.092
 cT1, 2 (n = 28) 347.8 ± 252.6
 cT3 (n = 38) 502.3 ± 560.2
Lymph node metastasis 0.496
 Absent (n = 15) 368.5 ± 255.6
 Present (n = 51) 456.9 ± 504.3
Clinical stage 0.408
 cStage II (n = 23) 373.5 ± 260.9
 cStage III, IVa (n = 43) 470.6 ± 536.3
Chemotherapy 0.028
 5-FU + cisplatin (n = 53) 368.3 ± 277.0
 5-FU + nedaplatin (n = 13) 716.1 ± 839.9
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Fig. 2. (a) Disease-specific survival, (b) recurrence-free survival, and (c) overall survival rates of patients with esophageal squamous 
cell carcinoma with pathological response grade ≥ 2 (n = 16) and grade < 2 (n = 50). (d) Disease-specific survival, (e) recurrence-
free survival, and (f) overall survival rates of patients with esophageal squamous cell carcinoma with PLR-CYFRAHigh (n = 45) and 
PLR-CYFRALow (n = 21).
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Table 4. Univariate and multivariate analyses of factors that might affect the disease-specific survival of patients 
with ESCC treated with NAC
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Age (years) 0.137
 < 70 1
 ≥ 70 0.447 0.154–1.294
Sex 0.744
 Female 1
 Male 1.222 0.367–4.069
Body mass index (kg/m2) 0.239
 < 18.5 1
 ≥ 18.5 0.617 0.276–1.379
Tumor location 0.266
 Upper, middle 1
 Lower 1.553 0.715–3.373
Invasion depth 0.160
 cT1, 2 1
 cT3 1.809 0.791–4.138
Lymph node metastasis 0.056
 Absent 1
 Present 7.027 0.953–51.841
Clinical stage 0.016 0.032
 cStage II 1 1
 cStage III, IVa 4.365 1.314–14.506 3.781 1.119–12.774
Chemotherapy 0.949
 5-FU + cisplatin 1
 5-FU + nedaplatin 1.014 0.658–1.564
SCC Ag 0.261
 < 1.5 1
 ≥ 1.5 1.246 0.849–1.829
CYFRA 0.407
 < 3.5 1
 ≥ 3.5 1.192 0.787–1.807
PNI 0.024 0.528
 ≥ 50 1 1
 < 50 2.411 1.124–5.168 1.298 0.578–2.916
mGPS 0.960
 0 1
 1, 2 1.023 0.411–2.547
NLR 0.124
 < 2.5 1
 ≥ 2.5 1.829 0.847–3.950
PLR 0.291
 < 150 1
 ≥ 150 1.509 0.703–3.239
PLR-CYFRA 0.023 0.030
 < 237.6 1 1
 ≥ 237.6 4.057 1.212–13.580 4.037 1.142–14.270
CI, confidence interval; HR, hazard ratio.
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Table 5. Univariate and multivariate analyses of factors that might affect the pathological response in patients 
with ESCC treated with NAC
Univariate analysis Multivariate analysis
Pathological response, n
Grade < 2 Grade ≥ 2 P OR 95% CI P
Age (years) 0.064
 < 70 38 8
 ≥ 70 12 8
Sex 1.000
 Female 6 2
 Male 44 14
Body mass index (kg/m2) 0.524
 < 18.5 15 3
 ≥ 18.5 35 13
Tumor location 0.859
 Upper, middle 30 10
 Lower 20 6
Invasion depth 0.199
 cT1, 2 19 9
 cT3 31 7
Lymph node metastasis 0.167
 Absent 9 6
 Present 41 10
Clinical stage 0.391
 cStage II 16 7
 cStage III, IVa 34 9
Chemotherapy 0.496
 5-FU + cisplatin 39 14
 5-FU + nedaplatin 11 2
SCC Ag 0.417
 < 1.5 32 12
 ≥ 1.5 18 4
CYFRA 0.162
 < 3.5 38 15
 ≥ 3.5 12 1
PNI 0.155
 ≥ 50 31 13
 < 50 19 3
mGPS 0.719
 0 41 12
 1, 2 9 4
NLR 0.009 0.681
 < 2.5 22 13 1
 ≥ 2.5 28 3 1.627 0.159–16.642
PLR 0.059
 < 150 24 12
 ≥ 150 26 4
PLR-CYFRA < 0.001 0.002
 < 237.6 8 13 1
 ≥ 237.6 42 3 31.481 3.438–288.303
CI, confidence interval; OR, odds ratio.
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environment.21 Additionally, cytokines and chemokines 
released from platelets promote the infiltration of other 
immune cells, including neutrophils and lymphocytes, 
into the tumor stroma, which induces the progression 
of inflammation.22 On the contrary, tumor markers are 
substances produced by tumor cells or by non-tumor 
cells in response to tumor cells that reflect the presence 
of tumors, tumor cell types, and tumor quantity.23 
Therefore, tumor markers directly reflect the disease 
activity of the tumor itself, and CYFRA is known to 
be a useful tumor marker in ESCC.24, 25 Furthermore, 
CYFRA has been reported to predict the response 
to chemotherapy in patients with non-small cell lung 
cancer.26, 27 On the other hand, it has been reported that 
other tumor markers such as SCC Ag and serum p53 
antibody, as well as PET-CT scan after NAC are useful 
in predicting the effect of NAC in ESCC patients.5, 28, 29 
Consistent with PLR-CYFRA in our results, these 
markers were shown to be independent predictors for 
pathological response to NAC in surgical specimens. 
The reason why different markers became independent 
predictors between these studies and our study may be 
due to the differences in patient backgrounds and the 
NAC regimens used. Here, we showed that the value of 
PLR multiplied by CYFRA is a highly accurate predic-
tor of chemotherapy efficacy and that pretreatment 
PLR-CYFRA might be an important biomarker for pa-
tients with ESCC who receive NAC. To our knowledge, 
this is the first report that demonstrates the utility of 
PLR in predicting the effects of NAC in ESCC. Several 
meta-analyses have reported the impact of PLR on the 
prognosis of patients with ESCC,30–32 and therefore, 
PLR is an important indicator during ESCC treatment. 
However, these reports included patients with various 
treatment strategies, and consequently, the clinical 
impact of PLR on NAC (the standard treatment for pa-
tients with locally advanced resectable ESCC in Japan) 
response was unclear. Yang et al. reported that PLR was 
more useful than NLR and PNI in predicting prognosis 
and treatment responses in patients with nonmetastatic 
ESCC who received postoperative chemotherapy10; 
however, the inf lammatory status of patients who 
received postoperative chemotherapy should differ from 
that of patients who received NAC because of the effects 
of surgery. Therefore, this study, which revealed the 
ability of PLR to predict the effects of NAC, presents 
a novel finding that is useful for ESCC treatment. We 
also showed that PLR-CYFRA was a useful prognostic 
factor for ESCC, and this was especially significant for 
DSS and RFS, but not for OS (Figs. 2d, e and f). This 
suggests that PLR-CYFRA may be more closely related 
to ESCC death, but it is not clear because there were 
only 7 patients who died of other diseases in this study. 
We acknowledge that this study has several limitations. 
First, this was a retrospective study with a small sample 
size, and therefore, a prospective study with a larger 
cohort is needed to validate the utility of PLR-CYFRA. 
Second, we did not evaluate the effect of NAC on 
metastatic lymph nodes, because the outcome of this 
study was a pathological response of the primary tumor, 
according to the Japanese Classification of Esophageal 
Cancer (11th edition).11, 12 However, approximately 20% 
of the patients in this study had no clinical lymph node 
metastasis, and the pathological response was correlated 
significantly with prognosis, as shown in Fig. 2; thus, 
we regard the results of this study as reliable. In conclu-
sion, pretreatment PLR-CYFRA was an independent 
predictor of the pathological response of patients with 
ESCC to NAC. According to these findings, we should 
consider more intensive NAC regimens for patients with 
ESCC with high pretreatment PLR-CYFRA, because 
patients with poor NAC responses also exhibit a poorer 
prognosis. We believe that a further prospective study 
of pretreatment PLR-CYFRA will lead to a novel and 
valuable biomarker for ESCC treatment.
Acknowledgments: The authors would like to thank Enago 
(www.enago.jp) for the English language review.
The authors declare no conflict of interest.
REFERENCES
 1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 
Global cancer statistics. CA Cancer J Clin. 2011;61:69-90. 
DOI: 10.3322/caac.20107,  PMID: 21296855
 2 Watanabe M, Tachimori Y, Oyama T, Toh Y, Matsubara H, 
Ueno M, et al.; Registration Committee for Esophageal Can-
cer of the Japan Esophageal Society. Comprehensive registry 
of esophageal cancer in Japan, 2013. Esophagus. 2021;18:1-24. 
DOI: 10.1007/s10388-020-00785-y,  PMID: 33047261
 3 Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, 
et al. A randomized trial comparing postoperative adjuvant 
chemotherapy with cisplatin and 5-f luorouracil versus 
preoperative chemotherapy for localized advanced squamous 
cell carcinoma of the thoracic esophagus (JCOG9907). Ann 
Surg Oncol. 2012;19:68-74. DOI: 10.1245/s10434-011-2049-9, 
PMID: 21879261
 4 Matsuda S, Kawakubo H, Okamura A, Takahashi K, Toihata 
T, Takemura R, et al. Distribution of Residual Disease and 
Recurrence Patterns in Pathological Responders After 
Neoadjuvant Chemotherapy for Esophageal Squamous Cell 
Carcinoma. Ann Surg. 2020 Oct 16. Online ahead of print. 
DOI: 10.1097/SLA.0000000000004436,  PMID: 33074909
 5 Okamura A, Matsuda S, Mayanagi S, Kanamori J, Imamura 
Y, Irino T, et al. Clinical significance of pretherapeutic serum 
squamous cell carcinoma antigen level in patients with 
neoadjuvant chemotherapy for esophageal squamous cell 
carcinoma. Ann Surg Oncol. 2021;28:1209-16. DOI: 10.1245/
s10434-020-08716-y,  PMID: 32524457
259
PLR-CYFRA—a novel biomarker in esophageal cancer
© 2021 Tottori University Medical Press
 6 Huang Y, Sun Y, Peng P, Zhu S, Sun W, Zhang P. Prognostic 
and clinicopathologic significance of neutrophil-to-lympho-
cyte ratio in esophageal squamous cell carcinoma: evidence 
from a meta-analysis. OncoTargets Ther. 2017;10:1165-72. 
DOI: 10.2147/OTT.S126637,  PMID: 28260931
 7 Zhou XL, Li YQ, Zhu WG, Yu CH, Song YQ, Wang WW, et 
al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker 
for patients with locally advanced esophageal squamous cell 
carcinoma treated with definitive chemoradiotherapy. Sci 
Rep. 2017;7:42581. DOI: 10.1038/srep42581,  PMID: 28195186
 8 Han L, Song Q, Jia Y, Chen X, Wang C, Chen P, et al. The 
clinical significance of systemic inflammation score in esoph-
ageal squamous cell carcinoma. Tumour Biol. 2016;37:3081-
90. DOI: 10.1007/s13277-015-4152-1,  PMID: 26423404
 9 Xie X, Luo KJ, Hu Y, Wang JY, Chen J. Prognostic value of 
preoperative platelet-lymphocyte and neutrophil-lymphocyte 
ratio in patients undergoing surgery for esophageal squamous 
cell cancer. Dis Esophagus. 2016;29:79-85. DOI: 10.1111/
dote.12296,  PMID: 25410116
 10 Yang Y, Xu H, Zhou L, Deng T, Ning T, Liu R, et al. Platelet 
to lymphocyte ratio is a predictive marker of prognosis and 
therapeutic effect of postoperative chemotherapy in non-
metastatic esophageal squamous cell carcinoma. Clin Chim 
Acta. 2018;479:160-5. DOI: 10.1016/j.cca.2018.01.013,  PMID: 
29325800
 11 Japanese Classification of Esophageal Cancer. 11th Edition: 
part I. Esophagus. 2017;14:1-36. PMID: 28111535.
 12 Japanese Classification of Esophageal Cancer. 11th Edition: 
part II and III. Esophagus. 2017;14:37-65. PMID: 28111536.
 13 .Onodera T, Goseki N, Kosaki G. [Prognostic nutritional 
index in gastrointestinal surgery of malnourished cancer pa-
tients]. Nihon Geka Gakkai zasshi. 1984;85:1001-5. Japanese.
 14 Proctor MJ, Morrison DS, Talwar D, Balmer SM, O’Reilly 
DSJ, Foulis AK, et al. An inflammation-based prognostic 
score (mGPS) predicts cancer survival independent of tumour 
site: a Glasgow Inflammation Outcome Study. Br J Cancer. 
2011;104:726-34. DOI: 10.1038/sj.bjc.6606087,  PMID: 
21266974
 15 Perkins NJ, Schisterman EF. The inconsistency of “optimal” 
cutpoints obtained using two criteria based on the receiver op-
erating characteristic curve. Am J Epidemiol. 2006;163:670-5. 
DOI: 10.1093/aje/kwj063,  PMID: 16410346
 16 Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index 
and its associated cutoff point. Biom J. 2005;47:458-72. DOI: 
10.1002/bimj.200410135,  PMID: 16161804
 17 Riesco A. Five-year cancer cure: relation to total amount of 
peripheral lymphocytes and neutrophils. Cancer. 1970;25:135-
40. DOI: 10.1002/1097-0142(197001)25:1<135::AID-
CNCR2820250120>3.0.CO;2-9,  PMID: 5410303
 18 Liu H, Wu Y, Wang Z, Yao Y, Chen F, Zhang H, et al. 
Pretreatment platelet-to-lymphocyte ratio (PLR) as a predic-
tor of response to first-line platinum-based chemotherapy 
and prognosis for patients with non-small cell lung cancer. J 
Thorac Dis. 2013;5:783-9. PMID: 24409356
 19 Wu Y, Li C, Zhao J, Yang L, Liu F, Zheng H, et al. 
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios 
predict chemotherapy outcomes and prognosis in patients 
with colorectal cancer and synchronous liver metastasis. 
World J Surg Oncol. 2016;14:289. DOI: 10.1186/s12957-016-
1044-9,  PMID: 27852294
 20 Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, 
Takashima T, et al. Platelet-lymphocyte ratio as a useful pre-
dictor of the therapeutic effect of neoadjuvant chemotherapy 
in breast cancer. PLoS One. 2016;11:e0153459. DOI: 10.1371/
journal.pone.0153459,  PMID: 27472762
 21 Suzuki K, Aiura K, Ueda M, Kitajima M. The influence of 
platelets on the promotion of invasion by tumor cells and inhi-
bition by antiplatelet agents. Pancreas. 2004;29:132-40. DOI: 
10.1097/00006676-200408000-00008,  PMID: 15257105
 22 Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, 
inflammation, and immunity. Int J Lab Hematol. 2013;35:254-
61. DOI: 10.1111/ijlh.12084,  PMID: 23590652
 23 Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, 
Jessup JM, et al. Tumor marker utility grading system: a 
framework to evaluate clinical utility of tumor markers. J Natl 
Cancer Inst. 1996;88:1456-66. DOI: 10.1093/jnci/88.20.1456, 
PMID: 8841020
 24 Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, 
Suzuki T. CYFRA 21-1 is a useful marker for esophageal 
squamous cell carcinoma. Cancer. 1997;79:1647-55. DOI: 
10.1002/(SICI)1097-0142(19970501)79:9<1647::AID-
CNCR3>3.0.CO;2-9,  PMID: 9128978
 25 Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki K, 
Watanabe S. CYFRA 21–1 as a tumor marker for squamous 
cell carcinoma of the esophagus. Dis Esophagus. 1998;11:35-
9. DOI: 10.1093/dote/11.1.35,  PMID: 29040480
 26 Pang L, Wang J, Jiang Y, Chen L. Decreased levels of serum 
cytokeratin 19 fragment CYFRA 21-1 predict objective 
response to chemotherapy in patients with non-small cell 
lung cancer. Exp Ther Med. 2013;6:355-60. DOI: 10.3892/
etm.2013.1171,  PMID: 24137188
 27 Sone K, Oguri T, Nakao M, Kagawa Y, Kurowaka R, Furuta 
H, et al. CYFRA 21-1 as a predictive marker for non-small 
cell lung cancer treated with pemetrexed-based chemo-
therapy. Anticancer Res. 2017;37:935-40. DOI: 10.21873/
anticanres.11402,  PMID: 28179355
 28 Hiyoshi Y, Yoshida N, Watanabe M, Kurashige J, Baba Y, 
Sakamoto Y, et al. The presence of serum p53 antibody 
predicts the pathological tumor response to neoadjuvant 
chemotherapy with docetaxel, cisplatin and fluorouracil 
(DCF) in esophageal squamous cell carcinoma. World J Surg. 
2017;41:480-6. DOI: 10.1007/s00268-016-3649-0,  PMID: 
27637603
 29 Miyata H, Yamasaki M, Takahashi T, Murakami K, 
Tanaka K, Yukinori K, et al. Determinants of response to 
neoadjuvant chemotherapy for esophageal cancer using 18F-
fluorodeoxiglucose positron emission tomography (18F-FDG-
PET). Ann Surg Oncol. 2014;21:575-82. DOI: 10.1245/s10434-
013-3343-5,  PMID: 24201746
 30 Zhao QT, Zhang XP, Zhang H, Duan GC. Prognostic role of 
platelet to lymphocyte ratio in esophageal cancer: A meta-
analysis. Oncotarget. 2017;8:112085-93. DOI: 10.18632/
oncotarget.22557,  PMID: 29340113
 31 Deng J, Zhang P, Sun Y, Peng P, Huang Y. Prognostic and 
clinicopathological significance of platelet to lymphocyte 
ratio in esophageal cancer: a meta-analysis. J Thorac Dis. 
2018;10:1522-31. DOI: 10.21037/jtd.2018.02.58,  PMID: 
29707302
 32 Zhang X, Wang Y, Zhao L, Sang S, Zhang L. Prognostic 
value of platelet-to-lymphocyte ratio in oncologic outcomes 
of esophageal cancer: A systematic review and meta-analysis. 
Int J Biol Marker. 2018:1724600818766889. PMID: 29683072.
